Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. 483
  6. /
  7. Biotika a.s.
483
•Biotika a.s.•June 1, 2018

Biotika a.s. – FDA 483, Jun 1, 2018

Record Details

On June 1, 2018, the FDA issued a Form 483 to Biotika, a pharmaceutical manufacturer located in Martin, Slovakia, following an inspection. The inspection revealed significant deficiencies in the company's quality control and manufacturing processes, particularly concerning the production of sterile drug products.

**Key Observations:**

1. **Lack of Aseptic Process Simulation:** Biotika failed to conduct aseptic process simulations (media fills) for its sterile drug products. This is a critical omission, as media fills are essential to validate the aseptic processing environment and ensure the sterility of the final product. The absence of these simulations means there is no documented evidence that the manufacturing process can consistently produce sterile drugs, posing a significant risk to patient safety.

2. **Inadequate Environmental Monitoring:** The environmental monitoring program in the aseptic processing areas was found to be deficient. Specifically, the company did not routinely monitor for viable microorganisms in critical areas during active sterile drug production. This lack of continuous monitoring means that potential microbial contamination events might go undetected, compromising the sterility of the drug products manufactured in these environments.

3. **Insufficient Investigation of Sterility Failures:** Biotika failed to adequately investigate sterility test failures. The document indicates that when sterility failures occurred, the investigations were not thorough enough to identify the root cause and implement effective corrective and preventive actions (CAPAs). This suggests a systemic issue in addressing quality deviations, increasing the risk of contaminated products reaching the market.

Company
Biotika a.s.
Inspection date
June 1, 2018
Product type
Drugs
Office
Center for Drug Evaluation and Research
Person
  • Tiara M. Brown (Consumer Safety Officer)
View Company Profile

ID · d34036cd-4b44-4ec7-8105-3ec2d4d8d0af

Other documents for Biotika a.s.
  • 483 - 2018-06-01June 1, 2018

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Biotika a.s.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.